Zenas BioPharma Announces Dosing of First Patient in Phase III Clinical Trial of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD).

Global Phase III INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and severe fibroinflammatory disease that typically affects multiple organs IgG4-RD is …

Read more

NuScale Power and RoPower announce the signing of the Phase 1 contract for front-end engineering and design work for the first SMR power plant in Romania

NuScale wins RoPower as the company’s second regular customer NuScale Power, LLC (NuScale) and Romania’s RoPower Nuclear SA (RoPower), equally owned by SN Nuclearelectrica SA and Nova Power Gas SA, …

Read more